(Q36008679)

11 August 2017

1 reference

title

Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy (English)

1 reference

11 August 2017

Baran R

1

1 reference

11 August 2017

Kaoukhov A

series ordinal

2

1 reference

11 August 2017

publication date

1 January 2005

1 reference

Journal of the European Academy of Dermatology and Venereology

11 August 2017

published in

1 reference

11 August 2017

volume

19

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

21-29

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.00988.X

11 August 2017

1 reference

Onychomycosis: current treatment and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.00988.X

Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada--a multicenter survey of 2001 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.00988.X

A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.00988.X

Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.00988.X

Superficial fungal infections. Topical and oral treatment of common types

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.00988.X

Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.00988.X

Drug delivery to the nail following topical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.00988.X

How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.00988.X

21 January 2018

Ciclopirox: an overview.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.00988.X

Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.00988.X

Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.00988.X

The past, present and future of antimycotic combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.00988.X

A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.00988.X

Combination therapy for onychomycosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.00988.X

Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.00988.X

10.1111/J.1468-3083.2004.00988.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference